Ebola

Re: Ebola

Waleed Bro and to all GS members…

WHO | Ebola virus disease

Ebola virus disease

   Fact sheet N°103

Updated September 2014

                [HR][/HR]  **Key facts**
  • Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans.
  • The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
  • The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks.
  • The first EVD outbreaks occurred in remote villages in Central Africa, near tropical rainforests, but the most recent outbreak in west Africa has involved major urban as well as rural areas.
  • Community engagement is key to successfully controlling outbreaks. Good outbreak control relies on applying a package of interventions, namely case management, surveillance and contact tracing, a good laboratory service, safe burials and social mobilisation.
  • Early supportive care with rehydration, symptomatic treatment improves survival. There is as yet no licensed treatment proven to neutralise the virus but a range of blood, immunological and drug therapies are under development.
  • There are currently no licensed Ebola vaccines but 2 potential candidates are undergoing evaluation.

[HR][/HR] Background

                            The Ebola virus causes an acute, serious illness which is  often fatal if untreated. Ebola virus disease (EVD) first appeared in  1976 in 2 simultaneous outbreaks, one in Nzara, Sudan, and the other in  Yambuku, Democratic Republic of Congo. The latter occurred in a village  near the Ebola River, from which the disease takes its name. 
                           The current outbreak in west Africa, (first cases notified in  March 2014), is the largest and most complex Ebola outbreak since the  Ebola virus was first discovered in 1976. There have been more cases and  deaths in this outbreak than all others combined. It has also spread  between countries starting in Guinea then spreading across land borders  to Sierra Leone and Liberia, by air (1 traveller only) to Nigeria, and  by land (1 traveller) to Senegal. 
                           The most severely affected countries, Guinea, Sierra Leone and  Liberia have very weak health systems, lacking human and  infrastructural resources, having only recently emerged from long  periods of conflict and instability. On August 8, the WHO  Director-General declared this outbreak a Public Health Emergency of  International Concern. 
                           A separate, unrelated Ebola outbreak began in Boende, Equateur, an isolated part of the Democratic Republic of Congo.
                           The virus family Filoviridae includes 3 genera: Cuevavirus,  Marburgvirus, and Ebolavirus. There are 5 species that have been  identified: Zaire, Bundibugyo, Sudan, Reston and Taï Forest. The first  3, Bundibugyo ebolavirus, Zaire ebolavirus, and Sudan ebolavirus have  been associated with large outbreaks in Africa. The virus causing the  2014 west African outbreak belongs to the Zaire species. 

Transmission

                            It is thought that fruit bats of the Pteropodidae family are  natural Ebola virus hosts.  Ebola is introduced into the human  population through close contact with the blood, secretions, organs or  other bodily fluids of infected animals such as  chimpanzees, gorillas,  fruit bats, monkeys, forest antelope and porcupines found ill or dead or  in the rainforest. 
                           Ebola then spreads through human-to-human transmission via  direct contact (through broken skin or mucous membranes) with the blood,  secretions, organs or other bodily fluids of infected people, and with  surfaces and materials (e.g. bedding, clothing) contaminated with these  fluids.
                           Health-care workers have frequently been infected while  treating patients with suspected or confirmed EVD. This has occurred  through close contact with patients when infection control precautions  are not strictly practiced.
                           Burial ceremonies in which mourners have direct contact with  the body of the deceased person can also play a role in the transmission  of Ebola. 
                           People remain infectious as long as their blood and body  fluids, including semen and breast milk, contain the virus. Men who have  recovered from the disease can still transmit the virus through their  semen for up to 7 weeks after recovery from illness.

Symptoms of Ebola virus disease

                            The incubation period, that is, the time interval from  infection with the virus to onset of symptoms is 2 to 21 days. Humans  are not infectious until they develop symptoms. First symptoms are the  sudden onset of fever fatigue, muscle pain, headache and sore throat.  This is followed by vomiting, diarrhoea, rash, symptoms of impaired  kidney and liver function, and in some cases, both internal and external  bleeding (e.g. oozing from the gums, blood in the stools). Laboratory  findings include low white blood cell and platelet counts and elevated  liver enzymes. 

Diagnosis

                            It can be difficult to distinguish EVD from other infectious  diseases such as malaria, typhoid fever and meningitis. Confirmation  that symptoms are caused by Ebola virus infection are made using the  following investigations: 
  • antibody-capture enzyme-linked immunosorbent assay (ELISA)

  • antigen-capture detection tests

  • serum neutralization test

  • reverse transcriptase polymerase chain reaction (RT-PCR) assay

  • electron microscopy

  • virus isolation by cell culture.

                           Samples from patients are an extreme biohazard risk;  laboratory testing on non-inactivated samples should be conducted under  maximum biological containment conditions.
    

Treatment and vaccines

                            Supportive care-rehydration with oral or intravenous fluids-  and treatment of specific symptoms, improves survival. There is as yet  no proven treatment available for EVD. However, a range of potential  treatments including blood products, immune therapies and drug therapies  are currently being evaluated. No licensed vaccines are available yet,  but 2 potential vaccines are undergoing human safety testing.

Prevention and control

                            Good outbreak control relies on applying a package of  interventions, namely case management, surveillance and contact tracing,  a good laboratory service, safe burials and social mobilisation.  Community engagement is key to successfully controlling outbreaks.  Raising awareness of risk factors for Ebola infection and protective  measures that individuals can take is an effective way to reduce human  transmission. Risk reduction messaging should focus on several factors:
  • Reducing the risk of wildlife-to-human transmission from contact with infected fruit bats or monkeys/apes and the consumption of their raw meat. Animals should be handled with gloves and other appropriate protective clothing. Animal products (blood and meat) should be thoroughly cooked before consumption.
  • Reducing the risk of human-to-human transmission from direct or close contact with people with Ebola symptoms, particularly with their bodily fluids. Gloves and appropriate personal protective equipment should be worn when taking care of ill patients at home. Regular hand washing is required after visiting patients in hospital, as well as after taking care of patients at home.
  • Outbreak containment measures including prompt and safe burial of the dead, identifying people who may have been in contact with someone infected with Ebola, monitoring the health of contacts for 21 days, the importance of separating the healthy from the sick to prevent further spread, the importance of good hygiene and maintaining a clean environment.

Controlling infection in health-care settings:

                            Health-care workers should always take standard precautions  when caring for patients, regardless of their presumed diagnosis. These  include basic hand hygiene, respiratory hygiene, use of personal  protective equipment (to block splashes or other contact with infected  materials), safe injection practices and safe burial practices.
                           Health-care workers caring for patients with suspected or  confirmed Ebola virus should apply extra infection control measures to  prevent contact with the patient’s blood and body fluids and  contaminated surfaces or materials such as clothing and bedding. When in  close contact (within 1 metre) of patients with EBV, health-care  workers should wear face protection (a face shield or a medical mask and  goggles), a clean, non-sterile long-sleeved gown, and gloves (sterile  gloves for some procedures).
                           Laboratory workers are also at risk. Samples taken from humans  and animals for investigation of Ebola infection should be handled by  trained staff and processed in suitably equipped laboratories.

WHO response

                            WHO aims to prevent Ebola outbreaks by maintaining  surveillance for Ebola virus disease and supporting at-risk countries to  developed preparedness plans. The document provides overall guidance  for control of Ebola and Marburg virus outbreaks:
  •  [Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation](http://www.who.int/entity/csr/resources/publications/ebola/manual_EVD/en/index.html) 
    
    
                            When an outbreak is detected WHO responds by supporting  surveillance, community engagement, case management, laboratory  services, contact tracing, infection control, logistical support and  training and assistance with safe burial practices.
                           WHO has developed detailed advice on Ebola infection prevention and control:
    
  •  [Infection  prevention and control guidance for care of patients with suspected or  confirmed Filovirus haemorrhagic fever in health-care settings, with  focus on Ebola](http://www.who.int/entity/csr/resources/publications/ebola/filovirus_infection_control/en/index.html)